Abstract Background T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a high risk of induction failure and poor outcomes, relapse due to drug resistance. Recent studies show that bromodomains extra-terminal (BET) protein inhibitors are promising anti-cancer agents. ARV-825, comprising BET inhibitor conjugated cereblon ligand, was recently developed attenuate the growth m...
